We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-7.6%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.27B
AUM Growth
-$1.19B
Cap. Flow
-$465M
Cap. Flow %
-8.83%
Top 10 Hldgs %
38.7%
Holding
148
New
20
Increased
18
Reduced
35
Closed
32

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$175M
2
HUM icon
Humana
HUM
+$51M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$50.2M
4
BLU
BELLUS Health Inc.
BLU
+$49.6M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$41M

Top Sells

Rank Stock Value
1
A icon
Agilent Technologies
A
+$66.7M
2
BSX icon
Boston Scientific
BSX
+$62.9M
3
BMY icon
Bristol-Myers Squibb
BMY
+$61M
4
MRK icon
Merck
MRK
+$51.7M
5
ILMN icon
Illumina
ILMN
+$51.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.14%
2 Financials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
76
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$12M 0.23%
150,000
+50,000
+50% +$4.24M
XFOR icon
77
X4 Pharmaceuticals
XFOR
$376M
$11.9M 0.23%
31,216
– –
KPTI icon
78
Karyopharm Therapeutics
KPTI
$156M
$10.3M 0.19%
71,060
-138,838
-66% -$18.8M
INSM icon
79
Insmed
INSM
$22.7B
$9.92M 0.19%
+562,300
New +$10.9M
NBRV
80
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$9.29M 0.18%
18,578
– –
RARX
81
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$8.91M 0.17%
+376,894
New +$11.2M
BIIB icon
82
Biogen
BIIB
$31.8B
$8.43M 0.16%
36,200
-51,500
-59% -$12M
TECX
83
Tectonic Therapeutic
TECX
$532M
$8.06M 0.15%
47,558
+38,725
+438% +$8.77M
SIBN icon
84
SI-BONE Inc
SIBN
$804M
$7.46M 0.14%
422,000
-563,368
-57% -$10.8M
PSNL icon
85
Personalis
PSNL
$1.26B
$7.1M 0.13%
483,842
+183,842
+61% +$3.48M
PBYI icon
86
Puma Biotechnology
PBYI
$399M
$6.85M 0.13%
636,600
+12,351
+2% +$133K
EHTH icon
87
CALL
eHealth
EHTH
$42.5M
$6.68M 0.13%
+100,000
New +$9.02M
ALDR
88
PUT
DELISTED
Alder Biopharmaceuticals
ALDR
$6.6M 0.13%
+350,000
New +$4M
XENE icon
89
Xenon Pharmaceuticals
XENE
$6.22B
$5.72M 0.11%
634,812
– –
VRNA
90
DELISTED
Verona Pharma
VRNA
$5.71M 0.11%
1,250,396
– –
HCAT icon
91
Health Catalyst
HCAT
$159M
$5.68M 0.11%
+179,598
New +$7.07M
CNST
92
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$5.4M 0.1%
835,842
– –
RNAC icon
93
Cartesian Therapeutics
RNAC
$223M
$5.04M 0.1%
95,969
– –
ARNA
94
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.04M 0.1%
110,000
– –
EPIX
95
DELISTED
ESSA Pharma
EPIX
$4.96M 0.09%
+1,471,853
New +$3.63M
SYBX
96
DELISTED
Synlogic
SYBX
$4.65M 0.09%
135,333
– –
NTLA icon
97
Intellia Therapeutics
NTLA
$1.49B
$4.37M 0.08%
327,600
– –
CTIC
98
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$4.18M 0.08%
5,000,000
– –
SRPT icon
99
CALL
Sarepta Therapeutics
SRPT
$1.62B
$3.77M 0.07%
+50,000
New +$5.9M
WHWK
100
Whitehawk Therapeutics
WHWK
$182M
$3.53M 0.07%
346,263
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2019 Portfolio in Review

As of Q3 2019, OrbiMed held 148 positions worth $5.27B, down 18% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed withdrew a net $465M in Q3 2019, closing 32 positions and reducing 35 holdings. Its most notable exit was Agilent Technologies, an estimated $66.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in SpringWorks Therapeutics worth $161M.

  • OrbiMed's largest Q3 2019 buy was SpringWorks Therapeutics: 7,406,307 shares worth $161M.
  • OrbiMed added most to Ultragenyx Pharmaceutical in Q3 2019, an estimated $41M increase.
  • OrbiMed's biggest Q3 2019 reduction was Boston Scientific, cutting an estimated $62.9M.
  • OrbiMed fully exited Agilent Technologies in Q3 2019, selling an estimated $66.7M.
  • OrbiMed's ten largest holdings make up 39% of its $5.27B portfolio in Q3 2019.
  • OrbiMed opened 20 new positions and closed 32 in Q3 2019.
  • OrbiMed's portfolio value fell 18% quarter-over-quarter to $5.27B.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.